Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Free Report) was the target of a significant drop in short interest in August. As of August 15th, there was short interest totalling 57,300 shares, a drop of 9.0% from the July 31st total of 63,000 shares. Based on an average trading volume of 32,300 shares, the short-interest ratio is presently 1.8 days. Approximately 0.8% of the company’s shares are short sold.
Cocrystal Pharma Price Performance
COCP traded down $0.06 on Tuesday, reaching $1.74. 17,311 shares of the company traded hands, compared to its average volume of 22,127. The stock’s 50 day moving average price is $2.08 and its 200-day moving average price is $1.88. Cocrystal Pharma has a 52-week low of $1.33 and a 52-week high of $3.10. The company has a market cap of $17.70 million, a price-to-earnings ratio of -1.00 and a beta of 1.41.
Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). As a group, equities research analysts forecast that Cocrystal Pharma will post -1.94 earnings per share for the current fiscal year.
Analyst Ratings Changes
Get Our Latest Report on Cocrystal Pharma
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.
Recommended Stories
- Five stocks we like better than Cocrystal Pharma
- How to Invest in Small Cap Stocks
- 3 Small Cap Stocks That Insiders Are Buying
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- What Does Downgrade Mean in Investing?
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.